Analysis of clinicopathological factors affecting the chemoradiotherapy sensitivity in advanced cervical squamous cell carcinoma treated

The average 5-year overall survival (OS) rate of locally advanced cervical cancer (LACC) is unsatisfactory, this study was to investigate the clinical factors of chemoradiotherapy resistance in cervical cancer after chemoradiation and to improve the efficacy. A total of 965 LACC patients treated with radical chemoradiotherapy, the patients were categorized into two groups: chemoradiotherapy-resistant and chemoradiotherapy-sensitive. The survival curve and survival rate were drawn by Kaplan-Meier method using the R language package. Log-rank test was applied to analyze the difference in the survival rate among the different groups, while COX regression models and logistic regression were applied to analyze the clinical factors affecting prognosis. The 5-year survival rate of the radiotherapy-sensitive group was approximately 40% higher than that of the radiotherapy-resistant group. Univariate analysis revealed that chemoradiotherapy sensitivity, tumor diameter, lymph node metastasis, hemoglobin levels, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and total radiotherapy time were prognostic factors for overall survival (OS) and progression-free survival (PFS). Multivariate analysis revealed that chemoradiotherapy sensitivity, age, PLR, and total radiotherapy time >8 weeks were independent prognostic factors for OS and PFS. The main clinical factors that contributed to the difference in the 5-year survival rate included the tumor stage, hemoglobin level, NLR, lymph node metastasis, and total radiotherapy time factors. Prognostic factors analyses revealed that OS and PFS affecting the efficacy of chemoradiotherapy for advanced cervical squamous cell carcinoma were associated with multiple clinical factors, and that chemoradiotherapy sensitivity, age, and PLR were independent prognostic factors for OS and PFS.

Chemoradiotherapy; Cervical squamous cell carcinoma; Prognostic factors; Sensitivity

[1] Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health. 2020; 8: e191–e203.

[2] Zhong L, Li K, Song L, Yin R. The effect of consolidation chemotherapy after concurrent chemoradiation on the prognosis of locally advanced cervical cancer: a systematic review and meta-analysis. Journal of Obstetrics and Gynaecology. 2022; 42: 830–837.

[3] Kim KH, Chang JS, Byun HK, Kim YB. A novel gene signature associated with poor response to chemoradiotherapy in patients with locally advanced cervical cancer. Journal of Gynecologic Oncology. 2022; 33: e7.

[4] Chen C, Wang L, Lin J, Jan J. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy. Journal of the Formosan Medical Association. 2015; 114: 231–237.

[5] Möller S, Mordhorst LB, Hermansson R, Karlsson L, Granlund U, Riemarsma C, et al. Combined external pelvic chemoradiotherapy and image-guided adaptive brachytherapy in treatment of advanced cervical carcinoma: experience from a single institution. Journal of Contemporary Brachytherapy. 2020; 12: 356–366.

[6] Jiang X, Tang H, Chen T. Epidemiology of gynecologic cancers in China. Journal of Gynecologic Oncology. 2018; 29: e7.

[7] van der Horst J, Siebers AG, Bulten J, Massuger LF, de Kok IM. Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004–2013. Cancer Medicine. 2017; 6: 416–423.

[8] Galic V, Herzog TJ, Lewin SN, Neugut AI, Burke WM, Lu Y, et al. Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecologic Oncology. 2012; 125: 287–291.

[9] Chen R, Lin Y, Chen C, Huang S, Chow S, Hsieh C. Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan. Gynecologic Oncology. 1999; 73: 184–190.

[10] Liu Y, Ni L, Wang S, Lv Q, Chen W, Ying S. Outcome and prognostic factors in cervical cancer patients treated with surgery and concurrent chemoradiotherapy: a retrospective study. World Journal of Surgical Oncology. 2018; 16: 18.

[11] Sturdza AE, Pötter R, Kossmeier M, Kirchheiner K, Mahantshetty U, Haie-Meder C, et al. Nomogram predicting overall survival in patients with locally advanced cervical cancer treated with radiochemotherapy including image-guided brachytherapy: a retro-EMBRACE study. International Journal of Radiation Oncology, Biology, Physics. 2021; 111: 168–177.

[12] Mayadev JS, Ke G, Mahantshetty U, Pereira MD, Tarnawski R, Toita T. Global challenges of radiotherapy for the treatment of locally advanced cervical cancer. International Journal of Gynecologic Cancer. 2022; 32: 436–445.

[13] Kim T, Park B, Kwack H, Kwon J, Kim J, Yoon S. Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation. Journal of Obstetrics and Gynaecology Research. 2012; 38: 1315–1320.

[14] Tovanabutra C, Asakij T, Rongsriyam K, Tangjitgamol S, Tharavichitkul E, Sukhaboon J, et al. Long-term outcomes and sites of failure in locally advanced, cervical cancer patients treated by concurrent chemoradiation with or without adjuvant chemotherapy: ACTLACC trial. Asian Pacific Journal of Cancer Prevention. 2021; 22: 2977–2985.

[15] Teh J, Yap SP, Tham I, Sethi VK, Chua EJ, Yeo R, et al. Concurrent chemoradiotherapy incorporating high-dose rate brachytherapy for locally advanced cervical carcinoma. International Journal of Gynecological Cancer. 2010; 20: 428–433.

[16] Queiroz ACM, Fabri V, Mantoan H, Sanches SM, Guimarães APG, Ribeiro ARG, et al. Risk factors for pelvic and distant recurrence in locally advanced cervical cancer. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2019; 235: 6–12.

[17] Endo D, Todo Y, Okamoto K, Minobe S, Kato H, Nishiyama N. Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: a retrospective analysis in a Japanese cohort. Journal of Gynecologic Oncology. 2015; 26: 12.

[18] Li X, Wei L, Zhang Y, Zhao L, Li W, Ping L, et al. The prognosis and risk stratification based on pelvic lymph node characteristics in patients with locally advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy. International Journal of Gynecologic Cancer. 2016; 26: 1472–1479.

[19] ATAHAN IL, ONAL C, OZYAR E, YILIZ F, SELEK U, KOSE F. Long-term outcome and prognostic factors in patients with cervical carcinoma: a retrospective study. International Journal of Gynecological Cancer. 2007; 17: 833–842.

[20] Parker K, Gallop-Evans E, Hanna L, Adams M. Five years’ experience treating locally advanced cervical cancer with concurrent chemoradiotherapy and high-dose-rate brachytherapy: results from a single institution. International Journal of Radiation Oncology, Biology, Physics. 2009; 74: 140–146.

[21] Peng Q-H, Chen K, Li J-Y, Chen L, Ye WJ. Analysis of treatment outcomes and prognosis after concurrent chemoradiotherapy for locally advanced cervical cancer. Frontiers in Oncology. 2022; 12: 926840.

[22] Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. International Journal of Gynecology & Obstetrics. 2018; 143: 22–36.

[23] Ma R, Zhang H, Zou L, Qu Y. Outcomes and prognostic factors of distant metastasis in patients with advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy. Zhonghua Fu Chan Ke Za Zhi. 2015; 50: 125–130. (In Chinese)

[24] Gennigens C, De Cuypere M, Seidel L, Hermesse J, Barbeaux A, Forget F, et al. Correlation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy. Cancer Medicine. 2020; 9: 8432–8443.

[25] Zhang Y, Wang L, Liu Y, Wang S, Shang P, Gao Y, et al. Preoperative neutrophil-lymphocyte ratio before platelet-lymphocyte ratio predicts clinical outcome in patients with cervical cancer treated with initial radical surgery. International Journal of Gynecologic Cancer. 2014; 24: 1319–1325.

[26] Trinh H, Dzul SP, Hyder J, Jang H, Kim S, Flowers J, et al. Prognostic value of changes in neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) for patients with cervical cancer undergoing definitive chemoradiotherapy (dCRT). Clinica Chimica Acta. 2020; 510: 711–716.

[27] Zhu M, Feng M, He F, Han B, Ma K, Zeng X, et al. Pretreatment neutrophil-lymphocyte and platelet-lymphocyte ratio predict clinical outcome and prognosis for cervical Cancer. Clinica Chimica Acta. 2018; 483: 296–302.

[28] Leng J, Wu F, Zhang L. Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, or monocyte-to-lymphocyte ratio in endometrial neoplasms: a systematic review and meta-analysis. Frontiers in Oncology. 2022; 12: 734948.

[29] Lee Y-Y, Choi CH, Kim H-J, Kim TJ, Lee JW, Lee JH, et al. Pretreatment neutrophil:lymphocyte ratio as a prognostic factor in cervical carcinoma. Anticancer Research. 2012; 32: 1555–1561.

[30] Wang D, Wu M, Feng F-Z, Huang HF, Yang JX, Shen K, et al. Pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios do not predict survival in patients with cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy. Chinese Medical Journal. 2013; 126: 1464–1468.

[31] Lee JW, Seol KH. Pretreatment neutrophil-to-lymphocyte ratio combined with platelet-to-lymphocyte ratio as a predictor of survival outcomes after definitive concurrent chemoradiotherapy for cervical cancer. Journal of Clinical Medicine. 2021; 10: 2199.

[32] NAKAMURA K, NISHIDA T, HARUMA T, HARAGA J, OMICHI C, OGAWA C, et al. Pretreatment platelet-lymphocyte ratio is an independent predictor of cervical cancer recurrence following concurrent chemoradiation therapy. Molecular and Clinical Oncology. 2015; 3: 1001–1006.

[33] Tas M, Yavuz A, Ak M, Ozcelik B. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in discriminating precancerous pathologies from cervical cancer. Journal of Oncology. 2019; 2019: 1–6.

[34] Zheng R, Huang M, Jin C, Wang H, Yu J, Zeng L, et al. Cervical cancer systemic inflammation score: a novel predictor of prognosis. Oncotarget. 2016; 7: 15230–15242.

[35] Liu J, Tang G, Zhou Q, Kuang W. Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy. Radiation Oncology. 2022; 17: 142.